Charles River re-ups Chiesi drug discovery contract

13-Mar-2017 - Last updated on 13-Mar-2017 at 19:53 GMT

Charles River Laboratories has extended its integrated respiratory program with Chiesi Farmaceutici, through which it identifies and tests candidates for preclinical development.

Parma, Italy-based Chiesi Farmaceutici SpA researches, develops, and markets drugs in the respiratory therapeutics, specialist medicine, and rare diseases areas.

According to the early-stage contract research organization (CRO), the integrated respiratory program with Chiesi was established in 2011.

“In the first six years, our relationship has yielded a number of patents and development candidates, and we’re optimistic that this strategic continuation will allow us to continue working on promising candidates with Chiesi,” Birgit Girshick, Corporate Senior Vice President, Global Discovery at Charles River, told Outsourcing-Pharma.com.

“With the continuation, we’ll provide them an extensive portfolio of integrated drug discovery capabilities,” added Girshick.

Provided services include medicinal chemistry, ADME/DMPK studies, pharmaceutics, in vitro assays, in vivo models, and safety pharmacology studies.

(Feature image: iStock/Pinkypills)